Direct Electrical Stimulation of Central Autonomic Network for Blood Pressure Control: a Mechanism Study
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorXuanwu Hospital, Beijing
About this trial
The primary objective of this research is to study direct electrical stimulation of central autonomic network for blood pressure control.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18-60 years, with no gender restrictions.
Free from severe systemic diseases.
Patients who have undergone stereoelectroencephalography electrode implantation.
Patients who have been informed of potential risks, consented to participate in this study, and signed the informed consent form.
Disqualifiers
Patients with scalp electrode hematoma or sub-electrode effusion after intracranial electrode implantation, who are unable to receive electrical stimulation.
Patients with intracranial structural lesions (e.g., encephalomalacia foci, vascular malformations, space-occupying lesions, etc.).
Pregnant women.
Patients who are unable to cooperate due to mental disorders or other causes.
Trial design
Design model
Single group
Treatments tested in this trial
direct electrical stimulation
Other interventionThe intervention consists of direct electrical stimulation delivered at three distinct frequencies (10 Hz, 50 Hz, and 120 Hz). A double-blind design will be employed to randomly assign one of these frequencies for a 30-second direct electrical stimulation session in each patient.
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: Direct electrical stimulationExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
blood pressure
Blood Pressure is defined as the blood pressure measurement obtained 30 minutes after the completion of direct electrical stimulation.
Time frame
up to 4 hoursLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: